Launch Of Vyvgart Exceeds Argenx’s Expectations
‘Pipeline in A Product’ Off To Strong Start In US
Executive Summary
Tim Van Hauwermeiren, CEO of Argenx, has been on the road with the firm's field force for the US launch of Vyvgart for generalized myasthenia gravis and has been enthused by the positive response from physicians.
You may also be interested in...
Argenx’s I.V. Vyvgart May See Continued Role In ITP, Despite SubQ Version Coming
The company presented Phase III data for the I.V. formulation at ASH showing a high response rate in pretreated patients, a difficult-to-treat population. It also has a subcutaneous version in Phase III.
Subcutaneous Efgartigimod Expands Payer Potential For Argenx’s Drug
With positive Phase III data for the injectable version of its myasthenia gravis therapy, the company expects most patients to use it over intravenous Vyvgart, opening more avenues for reimbursement.
UCB Advances Two-Drug Strategy For Myasthenia Gravis
Successful Phase III data for UCB’s C5 inhibitor zilucoplan adds to a similarly positive Phase III readout for its rozanolixizumab in December, but details are lacking. UCB is the only company with two mechanisms for MG.